The global sales of real-time PCR systems are estimated to be worth USD 6.3 billion in 2025 and are anticipated to reach a value of USD 13.7 billion by 2035. Sales are projected to rise at a CAGR of 8% over the forecast period between 2025 and 2035. The revenue generated by real-time PCR systems in 2024 was USD 5.9 billion. The industry is anticipated to exhibit a Y-o-Y growth of 7.4% in 2025.
The rising number of infectious diseases caused due to the food contamination is creating the huge demand for real-time PCR systems. The widespread spoilage is caused due to the contamination and the intake of such foods results in foodborne illness and therefore, the adoption of real-time PCR systems is increasing rapidly.
| Attributes | Key Insights |
|---|---|
| Estimated Size, 2025 | USD 6.3 billion |
| Projected Size, 2035 | USD 13.7 billion |
| Value-based CAGR (2025 to 2035) | 8% |
Moreover, an increasing number of people facing foodborne illness is creating the demand for real-time PCR systems in order to determine the presence of human pathogens and micro-organisms. Furthermore, the growing demand for packaged foods is also one of the major factors which drives the growth of real-time PCR systems market.
In addition, increasing food safety standards and rising focus on food security is compelling food & beverages manufactures towards the adoption of real-time PCR systems.
Real-time PCR systems are the laboratory equipment which are used to amplify the copies of specific DNA segments. The rising prevalence of chronic and infectious diseases is propelling the growth of the real-time PCR systems market. Furthermore, the advancements in various sectors such as forensics, diagnostics, and proteomics research is creating the potential growth opportunities for the real-time PCR Systems market.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The table below presents a comparative assessment of the variation in CAGR over six months for the base year (2024) and current year (2025). This analysis reveals crucial shifts in market performance and indicates revenue realization patterns, thus providing stakeholders with a better vision of the growth trajectory over the year.
The first half of the year, or H1, spans from January to June. The second half, H2, includes the months from July to December. In the first half (H1) of the semi-annual from 2025 to 2035, the business is predicted to surge at a CAGR of 7.4%, followed by a slightly higher growth rate of 8% in the second half (H2).
| Particular | Value CAGR |
|---|---|
| H1 2024 | 7.4% (2024 to 2034) |
| H2 2024 | 8.0% (2024 to 2034) |
| H1 2025 | 7.7% (2025 to 2035) |
| H2 2025 | 8.2% (2025 to 2035) |
Moving into the subsequent period, from H1 2025 to H2 2035, the CAGR is projected to increase slightly to 7.7% in the first half and remain relatively moderate at 8.2% in the second half. In the first half (H1) the market witnessed increase of 30 BPS while in the second half (H2), the market witnessed an increase of 20 BPS.
Advancements in Molecular Diagnostics Driving Real-Time PCR Market Growth with Multiplexing and High-Throughput Innovations
The rapid evolution of molecular diagnostics has significantly enhanced the efficiency and reliability of real-time PCR systems. A key advancement is multiplexing capability, which allows the simultaneous detection and quantification of multiple genetic targets in a single reaction. This innovation reduces reagent consumption, shortens test times, and enhances laboratory throughput, making it indispensable in infectious disease testing, oncology, and genetic research.
Moreover, high-throughput systems equipped with automated workflows have streamlined large-scale diagnostic operations, particularly during pandemics like COVID-19, where real-time PCR systems played a crucial role in global testing efforts.
For instance, in 2023, Thermo Fisher Scientific launched the QuantStudio Absolute Q Digital PCR system, integrating high-throughput capabilities with advanced multiplexing to improve diagnostic precision. Similarly, Roche Diagnostics introduced LightCycler 480 II with enhanced throughput and data accuracy. These technological breakthroughs underscore the growing reliance on real-time PCR in modern molecular diagnostics, propelling market growth.
Expanding Applications of Real-Time PCR in Oncology, Genetic Testing, and Food Safety with Recent Developments
The adoption of real-time PCR (qPCR) systems has significantly expanded beyond traditional infectious disease diagnostics, creating growth opportunities in oncology, genetic testing, and food safety. In oncology, qPCR is increasingly utilized for detecting cancer biomarkers and monitoring treatment efficacy.
Recent advancements include Thermo Fisher Scientific’s Oncomine assays, which enable targeted cancer gene detection using qPCR. Similarly, in genetic testing, qPCR’s precise quantification capabilities have made it a cornerstone technology for identifying hereditary conditions and conducting prenatal screening, with QIAGEN introducing new kits for multiplex genetic analysis in 2024.
In food safety, real-time PCR is gaining traction for rapid pathogen detection and ensuring regulatory compliance. Bio-Rad Laboratories launched a novel qPCR-based food safety testing solution in 2023, offering high accuracy for detecting contaminants such as Salmonella and Listeria. These developments highlight the versatility of qPCR, addressing diverse industry needs while driving its adoption across new, high-impact applications.
Rising R&D Investments in Genomics and Pharmaceuticals Driving Market Expansion with Notable Recent Developments
The surge in research and development (R&D) investments across genomics and the pharmaceutical sector is significantly boosting the adoption of real-time PCR systems. Governments and private organizations are channeling funds into genomic research to advance precision medicine and combat infectious diseases.
For instance, the National Institutes of Health (NIH) in the USA allocated substantial funding to COVID-19-related genomic studies, driving the demand for advanced qPCR systems. Similarly, pharmaceutical companies are leveraging qPCR for drug discovery and validation processes, emphasizing its role in speeding up clinical trials and regulatory compliance.
In 2023, Thermo Fisher Scientific launched a next-generation qPCR system with enhanced multiplexing capabilities to address evolving research needs. Likewise, Agilent Technologies expanded its product portfolio with cloud-based data integration, optimizing the efficiency of genomic studies. These developments highlight how rising R&D investments are fostering innovation, creating lucrative opportunities for the real-time PCR market.
The global real-time PCR systems market recorded a CAGR of 7.3% during the historical period between 2020 and 2024. The growth of real-time PCR systems market was positive as it reached a value of USD 5.9 billion in 2024 from USD 4.4 billion in 2020.
During 2020 to 2024, the real-time PCR (qPCR) systems market experienced a surge in demand due to the COVID-19 pandemic, which highlighted critical gaps in global diagnostic infrastructure. The pandemic drove widespread adoption of qPCR systems for SARS-CoV-2 testing, with hospitals, diagnostic centers, and research laboratories playing a pivotal role. However, the market faced significant challenges, including supply chain disruptions, reagent shortages, and manufacturing delays.
In response, companies like Thermo Fisher Scientific and QIAGEN rapidly scaled production, introduced compact and high-throughput systems, and focused on regional needs. Governments also stepped in with funding and subsidies to bolster diagnostic capacities. Innovations such as portable qPCR solutions enabled point-of-care testing in remote and hospital settings, significantly enhancing diagnostic reach.
Looking ahead to 2025 to 2035, the qPCR market is set to grow on the back of technological advancements and expanded applications. Factors like rising prevalence of chronic diseases, demand for personalized medicine, and automation in qPCR systems will drive this growth.
Emerging markets in Asia-Pacific, Latin America, and Africa are expected to play key roles, fueled by increased healthcare spending and government initiatives. Innovations in AI-powered diagnostics and cloud-based data integration will further enhance efficiency, ensuring qPCR remains vital for diagnostics and research.
Tier 1 companies comprise market leaders with a market revenue of above USD 100 million capturing a significant market share of 20-25% in the real-time PCR systems market. These market leaders are characterized by high production capacity and a wide product portfolio. These market leaders are distinguished by their extensive expertise in manufacturing across multiple packaging formats and a broad geographical reach, underpinned by a robust consumer base.
They provide a wide range of series including recycling, and manufacturing utilizing the latest technology meeting regulatory standards providing the highest quality. Prominent companies within Tier 1 include Thermo Fisher Scientific, Agilent Technologies, Abbott Laboratories, Danaher Corporation, Bio-Rad Laboratories Inc., QIAGEN, GE Healthcare, Abbott, Hoffmann-La Roche AG, and Fluidigm Corporation.
Tier 2 and other includes the majority of small-scale companies operating at the local presence and serving niche markets having revenue below USD 100 million. These companies are notably oriented towards fulfilling local market demands and are consequently classified within the tier 2 share segment.
They are small-scale players and have limited geographical reach. Tier 2, within this context, is recognized as an unorganized market, denoting a sector characterized by a lack of extensive structure and formalization when compared to organized competitors.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The section below covers the industry analysis for the real-time PCR systems market for different countries. Market demand analysis on key countries is provided. The United States is anticipated to remain at the forefront in North America, with a value share of 64.6% through 2035. In East Asia, China is projected to witness a CAGR of 6.9% by 2035.
| Countries | Value CAGR (2025 to 2035) |
|---|---|
| United States | 7.1% |
| Canada | 8.9% |
| Germany | 8.7% |
| China | 7.6% |
| Japan | 8.2% |
The United States is a dominant player in the global real-time PCR (qPCR) systems market, with North America holding the majority share in the industry. This is primarily due to major manufacturers, leading research facilities, and a vibrant biotechnology industry that encourages innovative molecular diagnostics developments.
For instance, Roche just launched its LightCycler PRO System in early 2023. This device is an ultra-high-performance qPCR platform designed with both clinical research and diagnostic testing in mind-bridging translational research and the in vitro diagnostical landscape.
In 2023, United States healthcare spending increased by 7.5% to USD 4.9 trillion, which is equivalent to 17.6% of the country's GDP. Such significant investment has been made for the betterment of healthcare infrastructure and technology, further solidifying its position as a leader in qPCR technology.
Germany is a leading country in Real-Time PCR (Polymerase Chain Reaction) systems. Molecular diagnostics and biotechnology are highly valued in Germany, and companies like QIAGEN and Analytik Jena lead the country's innovation and global exports in this field. Advanced PCR systems can be produced due to strong infrastructure and expertise in Germany, giving it a competitive edge in the world market.
Recent developments that have come to light and indicate Germany's dominance include the QIAGEN, which launched its QIAsymphony Dx Real-Time PCR System in February 2023. This advanced system is proved to be user-friendly and efficient. Such innovation projects show Germany's adherence to maintaining a leadership position in this field.
Germany's annual R&D expenditure, reported at 3.14% of GDP in 2021 (approximately €112.6 billion), demonstrates its consistent focus on innovation. This robust investment secures its place as a leading country for developing advanced medical technologies and diagnostic tools.
Japan is another significant player of the global real-time PCR system market, known for high technology and high precision engineering. The leading players in the high-quality PCR manufacturing companies in the country are Takara Bio Inc., Sysmex Corporation, and Hitachi High-Tech Corporation. These organizations are keenly focused on bringing out advanced high-quality products aimed at different types of applications and uses, namely molecular diagnostics and infectious disease tests, as well as research use.
Japan's efforts in research and development (R&D) cement its position firmly in the sectors of biotechnology and medical devices. The country is one of the top spenders of innovation globally by investing more than 3.3% of GDP in R&D every year. This commitment toward R&D enables continuous improvements of PCR technology, which will sustain and possibly add to Japan's leadership in Real-Time PCR systems through years of future development
The section contains information about the leading segments in the industry. By product type, real-time PCR consumables and reagents segment is estimated to grow at a CAGR of 7.6% throughout 2035. Additionally, hospitals is projected to expand at 7.2% by 2035.
| Product Type | Real-time PCR Consumables and Reagents |
|---|---|
| Value Share (2035) | 61.2% |
Consumables and reagents have consistently been the dominant products in the global PCR market. In 2024, consumables and reagents made up 65% of real time PCR market share, with high demand for SARS-CoV-2 testing.
In November 2023, QIAGEN launched three new kits compatible with its QIAcuity systems. These kits help to improve the efficiency and accuracy of real time PCR workflows. These innovations are being made to keep up with the demand for high-precision, high-speed diagnostic tools in the wake of emerging infectious diseases.
The continuous need for consumables and reagents in every qPCR test, coupled with their recurring nature, ensures sustained market growth. As research and clinical diagnostics expand, the reliance on these essential components is expected to drive the market forward, solidifying their leading position in the qPCR industry.
| End User | Hospitals |
|---|---|
| Value Share (2035) | 22.3% |
The use of qPCR systems in hospitals leads to the dominance of the end-use segment in the Real-Time PCR (qPCR) systems market. Hospitals have been critical units for diagnostics and patient care. Hospitals always require qPCR for several applications. Some of them include applications in infectious disease detection, genetic testing, and oncology diagnostics.
The rising cases of COVID-19, influenza, and other diseases increase the demand for qPCR systems in hospitals, facilitating rapid and accurate diagnostic capabilities. The need for personalized medicine and point-of-care testing is further driving the trend in clinical settings.
As of 2023, across the globe, hospitals had adopted third-generation qPCR systems for detecting influenza and RSV (Respiratory Syncytial Virus) as routine diagnostics. Company such as Thermo Fisher Scientific and Bio-Rad Laboratories launched hospital-centric solutions, one of which comprised compact qPCR systems that made faster diagnosis easier, allowing a hospital to develop more efficient workflows and better results.
Although qPCR users would be research laboratories and diagnostic centers, hospitals continue to hold the top position since they perform testing regularly and in huge numbers. With growing healthcare infrastructure investment and increasing molecular diagnostics expenditures, hospitals are likely to remain the highest end users of qPCR systems for the next few years.
The section provides comprehensive assessments and insights that highlight current opportunities and emerging trends for companies in developed and developing countries. It analyses advancements in manufacturing and identifies the latest trends poised to drive new applications in the market.
The key players in the market are actively enhancing their market presence and competitiveness through different strategies by incorporating advanced technologies like variable-speed compressors, intelligent controls, and integration with renewable energy sources to improve energy efficiency and environmental sustainability.
Significant players are further introducing new products to address the increasing need for cutting-edge solutions in various end-use sectors. Geographic expansion is another important strategy that is being embraced by reputed companies. Start-ups are likely to emerge in the sector through 2035, thereby making it more competitive.
Recent Industry Developments
In terms of product type, the industry is divided into real-time PCR instruments and real-time PCR consumables and reagents.
In terms of application, the industry is divided blood and oncology testing, pathogen testing, research & development and forensic science.
In terms of end use, the industry is divided into clinical research organizations, research laboratories, educational institutes, diagnostic centres, hospitals and other end user.
Key regions of North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia Pacific and Middle East & Africa have been covered in the report.
The global real-time PCR systems industry is projected to witness a CAGR of 8% between 2025 and 2035.
The global real-time PCR systems industry stood at USD 5.9 billion in 2024.
The global real-time PCR systems industry is anticipated to reach USD 13.7 billion by 2035 end.
The key players operating in the global real-time PCR systems industry include Thermo Fisher Scientific, Agilent Technologies, Abbot Laboratories, Danaher Corporation, Bio-Rad Laboratories Inc. and QIAGEN.
| Market Value, 2025 | USD 575.7 million |
|---|---|
| Market Value, 2035 | USD 868.7 million |
| Value CAGR (2025 to 2035) | 4.2% |
| Market Value (2022) | USD 160 Million |
|---|---|
| Market Anticipated Value (2032) | USD 250 Million |
| Market Projected CAGR (2022 to 2032) | 4% to 5% |
| Expected Market Value (2022) | USD 2.71 Billion |
|---|---|
| Anticipated Forecast Value (2032) | USD 6 Billion |
| Projected CAGR (2022 to 2032) | 8.3% |
Explore Laboratory Equipment & Apparatus Insights
View Reports
Real-time PCR (Polymerase Chain Reaction) Systems Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
